Kendall Capital Partners invests in early stage companies that are incubated by scientific labs from top universities, upholding the concept of “value creation” with commitment to support entrepreneurs using our extensive network of resources NEWS Kendall Capital Partners Led Series A Round in Rejuvenate Bio, April 2021 Rejuvenate Bio banks $10M to advance gene therapy for aging in humans and dogs Kendall Capital Partners Invested in Eyenuk Series A, October 2022 Eyenuk, a global provider of AI-powered eye screenings, scores $26M to expand reach in 18 countries EpiBone, Inc. Secures Funding Round Led by Kendall Capital Partners, November 2024 EpiBone, Inc. Secures Funding Round to Accelerate Global Expansion of Clinical Trials Kendall Capital Partners Invested in Centivax Series A, July 2025 Centivax closed $45M, moving into clinical trial with its universal flu vaccine